Quantcast
Last updated on April 24, 2014 at 16:36 EDT

Latest Certolizumab pegol Stories

2009-05-18 07:00:00

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to...

2009-05-15 06:00:00

Cimzia(R) (certolizumab pegol) now offered in an innovative prefilled syringe designed in partnership with OXO GOOD GRIPS(R) ATLANTA, May 15 /PRNewswire/ --- UCB today announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S. for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy, is...

2009-05-14 08:46:00

Nektar Advanced Polymer Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB Collaboration SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha), for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia(R) utilizes...

2009-05-14 06:00:00

-- UCB offers Cimzia(R) (certolizumab pegol), a treatment option for adults with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, to U.S. patients in an exclusively designed prefilled syringe resulting from the UCB partnership with OXO(R) -- Rheumatoid arthritis patients directly involved with UCB and OXO(R) in the development of the new Cimzia(R) prefilled syringe -- Cimzia(R) prefilled syringe designed to make self-administration easy for...

2008-12-05 07:00:00

Improved outcomes for fistula closures observed in PRECiSE 2 trial under maintenance therapy with stable dosing of CIMZIA(R) every four weeks HOLLYWOOD, Fla., Dec. 5 /PRNewswire-FirstCall/ -- Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn's & Colitis Foundation's Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn's disease patients who had open fistulas at baseline had closure of fistulas...

2008-10-30 15:00:14

UCB announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year. "In the RAPID 1 study Cimzia(R), together with MTX, had a rapid onset of...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified...

2008-10-08 09:00:00

BURLINGTON, ONTARIO--(Marketwire - Oct. 8, 2008) - UCB Pharma Canada today announced data presented at the American College of Gastroenterology (ACG) Scientific Meeting, in Orlando, Florida, from two studies demonstrating that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate-to-severe Crohn's disease (CD). A third study presented by UCB provided...

2008-10-07 09:00:56

UCB, a Belgium-based biopharmaceutical and specialty chemical company, has presented positive data from a large, prospective study investigating endoscopic improvement in Crohn's disease with a biologic compound. The data showed that Cimzia (certolizumab pegol) - the only PEGylated anti-TNF alpha (tumor necrosis factor alpha) - significantly improved endoscopic lesions and induced endoscopic response (as assessed by the Crohn's Disease Endoscopic Index of Severity (CDEIS)) within 10 weeks...

2008-10-07 09:00:14

ORLANDO, Fla. Oct. 7 /PRNewswire-FirstCall/ -- Data from two studies presented this week by UCB at the American College of Gastroenterology (ACG) Annual Meeting demonstrate that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate to severe Crohn's disease (CD). A third study presented by UCB provided an estimated comparison of treatment costs...